Abstract:Natural, extracellular membrane vesicles secreted by Gram-negative bacteria, outer membrane vesicles (OMVs), contain numerous pathogen-associated molecular patterns which can activate systemic immune responses. Previous studies have shown that OMVs induce strong IFN-γ- and T cell-mediated anti-tumor effects in mice. However, IFN-γ is known to upregulate immunosuppressive factors in the tumor microenvironment, especially the immune checkpoint programmed death 1 ligand 1 (PD-L1), which may hamper T cell function and limit immunotherapeutic effectiveness. Here, we report the development of genetically engineered OMVs whose surface has been modified by insertion of the ectodomain of programmed death 1 (PD1). This genetic modification does not affect the ability of OMVs to trigger immune activation. More importantly, the engineered OMV-PD1 can bind to PD-L1 on the tumor cell surface and facilitate its internalization and reduction, thereby protecting T cells from the PD1/PD-L1 immune inhibitory axis. Through the combined effects of immune activation and checkpoint suppression, the engineered OMVs drive the accumulation of effector T cells in the tumor, which, in turn, leads to a greater impairment of tumor growth, compared with not only native OMVs but also the commonly used PD-L1 antibody. In conclusion, this work demonstrates the potential of bioengineered OMVs as effective immunotherapeutic agents that can comprehensively regulate the tumor immune microenvironment to effect markedly increased anti-tumor efficacy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c03776?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c03776</a>.Additional figures for further characterization of OMVs and OMV-PD1 (Supplementary Figure 1); BMDCs mature, TLRs response, and CD49b+ NK cells quantification (Supplementary Figures 2, 3, and 4); PD-L1 upregulation in tumor cells in response to OMVs or IFN-γ (Supplementary Figure 5); immunoprecipitation results with OMVs and OMV-PD1 (Supplementary Figure 6); cell-binding and uptake studies (Supplementary Figures 7 and 8); intracellular fate of OMVs and OMV-PD1 (Supplementary Figure 9); proportion of proliferative T cells (Supplementary Figure 10); OMV-PD1 blood retention time (Supplementary Figure 11); cytotoxicity on B16, CT26, and HUVEC (Supplementary Figure 12); B16 and CT26 tumor images and average body weight (Supplementary Figure 13); analysis of effector memory T cells (CD3+CD8+CD44+CD62L–), CD49b+ cells, and CD11b+ cells (Supplementarys Figure 14 and 15); quantification analysis of PDL1 (Supplementary Figure 16); percentage of IFN-γ+CD8+ T cells (Supplementary Figure 17); biosafety of OMVs (Supplementary Figures 18 and 19); effects of immunotherapy on organ histology (Supplementary Figure 20); and Pearson's colocalization coefficiencts (PCC) of PD-L1 and acid compartments (Supplementary Table 1) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c03776/suppl_file/nn0c03776_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Engineered T cell extracellular vesicles displaying PD-1 boost anti-tumor immunity

Selective Enrichment and Detection of PD-L1 Positive Extracellular Vesicles Derived from Human Plasma and Patient Derived Tumor Cells

Abstract 7251: Surface-engineered extracellular vesicles to modulate antigen-specific T cell expansion for cancer immunotherapy

PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy

Truncated PD1 Engineered Gas‐Producing Extracellular Vesicles for Ultrasound Imaging and Subsequent Degradation of PDL1 in Tumor Cells

Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies

Engineered IL-15/IL-15Rα-expressing Cellular Vesicles Promote T Cell Anti-Tumor Immunity

BxPC-3-Derived Small Extracellular Vesicles Induce FOXP3+ Treg Through ATM-AMPK-Sirtuins-Mediated FOXOs Nuclear Translocations

Engineered Extracellular Vesicles to Enhance Antigen Presentation for Boosting Light‐Driven Tumor Immunotherapy

Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity

Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer

Cellular Vesicles Expressing PD-1-blocking Scfv Reinvigorate T Cell Immunity Against Cancer

Engineered Extracellular Vesicles to Enhance Antigen Presentation for Boosting Light‐Driven Tumor Immunotherapy (Small 49/2023)

Viral Protein‐Pseudotyped and siRNA‐Electroporated Extracellular Vesicles for Cancer Immunotherapy

Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy

Cancer Immunotherapy: PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy (Adv. Mater. 22/2018)

PD-L1 Antibodies-Armed Exosomal Vaccine for Enhanced Cancer Immunotherapy by Simultaneously in Situ Activating T Cells and Blocking PD-1/PD-L1 Axis

Engineered Cells for Costimulatory Enhancement Combined with IL-21 Enhance the Generation of PD-1-disrupted CTLs for Adoptive Immunotherapy.

Immunosuppressive Effect of Small Extracellular Vesicle PD-L1 is Restricted by Co-Expression of CD80

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy